生物标记物在分子诊断中对靶向治疗的应用
Application of Biomarkers for Common Cancers in Molecular Diagnosis
DOI: 10.12677/MD.2019.92007, PDF,   
作者: 韩建冬, 王美玲, 额尔敦, 杜艳青, 梁凤英, 格根塔娜：内蒙古医科大学，内蒙古 呼和浩特
关键词: 分子；诊断；肿瘤；Molecular； Diagnosis； Tumor
摘要: 目前可以从通过活组织检查或手术获得的肿瘤样本中收获肿瘤的DNA。可以使用高通量基因分型和或测序平台进行肿瘤DNA的完整分子谱分析。预测性生物标志物的鉴定将允许用特异性靶标(激酶抑制剂和MoAb，单克隆抗体)和常规药剂进行个体化治疗。但生物标记物在分子诊断中对靶向治疗的应用仍是分子诊断学中的关键，本文将概述生物标记物在分子诊断中对靶向治疗的关键应用。
Abstract: Tumor DNA can now be harvested from tumor samples obtained by biopsy or surgery. Complete molecular profiling of tumor DNA can be performed using high throughput genotyping and or se-quencing platforms. Identification of predictive biomarkers will allow for individualized treatment with specific targets (kinase inhibitors and MoAbs, monoclonal antibodies) and conventional agents. However, the application of biomarkers to targeted therapies in molecular diagnostics remains the key to molecular diagnostics. This article will outline the key applications of biomarkers for targeted therapies in molecular diagnostics.
文章引用：韩建冬, 王美玲, 额尔敦, 杜艳青, 梁凤英, 格根塔娜. 生物标记物在分子诊断中对靶向治疗的应用[J]. 医学诊断, 2019, 9(2): 35-41. https://doi.org/10.12677/MD.2019.92007

参考文献

[1] Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A. and Bernards, R. (2012) Unresponsiveness of Colon Cancer to BRAF (V600E) Inhibition through Feedback Activation of EGFR. Nature, 483, 100-103. [Google Scholar] [CrossRef] [PubMed]
[2] Ribas, A. and Flaherty, K.T. (2011) BRAF Targeted Therapy Changes the Treatment Paradigm in Melanoma. Nature Reviews Clinical Oncology, 8, 426-433. [Google Scholar] [CrossRef] [PubMed]
[3] Sasaki, T., Rodig, S.J., Chirieac, L.R. and Janne, P.A. (2010) The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer. European Journal of Cancer, 46, 1773-1780. [Google Scholar] [CrossRef] [PubMed]
[4] Scagliotti, G., Stahel, R.A., Rosell, R., Thatcher, N. and Soria, J.C. (2012) ALK Translocation and Crizotinib in Non-Small Cell Lung Cancer: An Evolving Paradigm in Oncology Drug Development. European Journal of Cancer, 48, 961-973. [Google Scholar] [CrossRef] [PubMed]
[5] Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., Akhavanfard, S., Heist, R.S., Temel, J., Christensen, J.G., Wain, J.C., Lynch, T.J., Vernovsky, K., Mark, E.J., Lanuti, M., Iafrate, A.J., Mino-Kenudson, M. and Engelman, J.A. (2011) Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 3, 75ra26. [Google Scholar] [CrossRef] [PubMed]
[6] Shaw, A.T. and Solomon, B. (2011) Targeting Anaplastic Lymphoma Kinase in Lung Cancer. Clinical Cancer Research, 17, 2081-2086. [Google Scholar] [CrossRef] 
[7] Smalley, K.S. and McArthur, G.A. (2012) The Current State of Targeted Therapy in Melanoma: This Time It’s Personal. Seminars in Oncology, 39, 204-214. [Google Scholar] [CrossRef] [PubMed]
[8] Sotiriou, C. and Pusztai, L. (2009) Gene-Expression Signatures in Breast Cancer. The New England Journal of Medicine, 360, 790-800. [Google Scholar] [CrossRef] 
[9] Su, K.Y., Chen, H.Y., Li, K.C., Kuo, M.L., Yang, J.C., Chan, W.K., Ho, B.C., Chang, G.C., Shih, J.Y., Yu, S.L. and Yang, P.C. (2012) Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients with Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 30, 433-440. [Google Scholar] [CrossRef] 
[10] Subramanian, J. and Govindan, R. (2008) Molecular Genetics of Lung Cancer in People Who Have Never Smoked. The Lancet Oncology, 9, 676-682. [Google Scholar] [CrossRef] 
[11] Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., Lim Choi, Y., Satoh, Y., Okumura, S., Nakagawa, K., Mano, H. and Ishikawa, Y. (2012) RET, ROS1 and ALK Fusions in Lung Cancer. Nature Medicine, 18, 378-381. [Google Scholar] [CrossRef] [PubMed]
[12] Tran, B., Dancey, J.E., Kamel-Reid, S., McPherson, J.D., Bedard, P.L., Brown, A.M., Zhang, T., Shaw, P., Onetto, N., Stein, L., Hudson, T.J., Neel, B.G. and Siu, L.L. (2012) Cancer Genomics: Technology, Discovery, and Translation. Journal of Clinical Oncology, 30, 647-660. [Google Scholar] [CrossRef] 
[13] Van Cutsem, E., Kohne, C.H., Lang, I., Folprecht, G., Nowacki, M.P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., Schlichting, M., Zubel, A., Celik, I., Rougier, P. and Ciardiello, F. (2011) Cetuximab plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. Journal of Clinical Oncology, 29, 2011-2019. [Google Scholar] [CrossRef] 
[14] van Krieken, J.H., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F.T., Quirke, P., Flejou, J.F., Plato Hansen, T., de Hertogh, G., Jares, P., Langner, C., Hoefler, G., Ligtenberg, M., Tiniakos, D., Tejpar, S., Bevilacqua, G. and Ensari, A. (2008) KRAS Mutation Testing for Predicting Response to anti-EGFR Therapy for Colorectal Carcinoma: Proposal for an European Quality Assurance Program. Virchows Archiv, 453, 417-431. [Google Scholar] [CrossRef] [PubMed]
[15] Weinstein, I.B. (2002) Cancer. Addiction to Oncogenes—The Achilles Heal of Cancer. Science, 297, 63-64. [Google Scholar] [CrossRef] [PubMed]
[16] Engel, N., Gossauer, A., Gruber, K. and Kratky, C. (1993) X-Ray Molecular Structure of a Red Bilin Derivative from Chlorella Protothecoides. 4th Communication on Chlorophyll Catabolism. Helvetica Chimica Acta, 76, 2236-2238. [Google Scholar] [CrossRef] 
[17] Boiadjiev, S.E. and Lightner, D.A. (2000) Chirality Inversion in a Molecular Exciton. Journal of the American Chemical Society, 122, 378-383. [Google Scholar] [CrossRef] 
[18] Dan Pantos, G., Salome Rodriguez-Morgade, M., Torres, T., Lynch, V.M. and Sessler, J.L. (2006) 2-Amino-3, 4-Diethylpyrrole Derivatives: New Building Blocks for Coiled Structures. Chemical Communications, No. 20, 2132-2134. [Google Scholar] [CrossRef] 
[19] Haketa, Y. and Maeda, H. (2011) From Helix to Macrocycle: Anion-Driven Conformation Control of π-Conjugated Acyclic Oligopyrroles. Chemistry: A European Journal, 17, 1485-1492. [Google Scholar] [CrossRef] [PubMed]
[20] Haketa, Y., Bando, Y., Takaishi, K., Uchiyama, M., Muranaka, A., Naito, M., Shibaguchi, H., Kawai, T. and Maeda, H. (2012) Asymmetric Induction in the Preparation of Helical Receptor-Anion Complexes: Ion-Pair Formation with Chiral Cations. Angewandte Chemie, 124, 8091-8095. [Google Scholar] [CrossRef] 
[21] Juwarker, H. and Jeong, K.-S. (2010) Anion-Controlled Foldamers. Chemical Society Reviews, 39, 3664-3674. [Google Scholar] [CrossRef] [PubMed]
[22] Dolphin, D., Harris, R.L.N., Huppatz, J.L., Johnson, A.W., Kay, I.T. and Leng, J. (1966) The Synthesis of 5,5-Bi-(Dipyrromethenyls) and Related Compounds. Journal of the Chemical Society C, 98-106. [Google Scholar] [CrossRef] 
[23] Murakami, Y., Matsuda, H. and Kanaoka, Y. (1971) Transition-Metal Complexes of Pyrrole Pigments. III. Copper(II) and Zinc(II) Complexes of 1,19-Dideoxy-8,12-Dicarbethoxy-1,3,7,13,17,19-Hexamethylbiladiene-ac. Bulletin of the Chemical Society of Japan, 44, 409-415.
[24] Struckmeier, G., Thewalt, U. and Fuhrhop, J.-H. (1976) Structures of Zinc Octaethyl Formylbiliverdinate Hydrate and Its Dehydrated Bis-Helical Dimer. Journal of the American Chemical Society, 98, 278-279. [Google Scholar] [CrossRef] 
[25] Sheldrick, W.S. and Engel, J. (1980) X-Ray Crystal Structure of the Zinc Complex of 1,2,3,7,8,12,13,17,18,19-Decame- thylbiladiene-a,c. Journal of the Chemical Society, Chemical Communications, 23, 5-6.
[26] Thompson, A. and Dolphin, D. (2000) Double-Helical Dinuclear Bis(dipyrromethene) Complexes Formed by Self-Assembly. The Journal of Organic Chemistry, 65, 7870-7877. [Google Scholar] [CrossRef] [PubMed]